AstraZeneca PLC said Thursday that ALXN1840 met the primary endpoint in a FoCus Phase 3 trial for Wilson disease, showing an improvement in copper mobilization from tissues.
The pharmaceutical giant said that ALXN1840 demonstrated about three times more copper mobilization from tissues than standard-of-care treatments.
Wilson disease is a rare and progressive genetic condition in which the body's pathway for removing excess copper is compromised.
Separately AstraZeneca said that Forxiga has been approved in Japan for the treatment of chronic kidney disease in patients with and without type-2 diabetes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.